arrow
R

Richard D. DiMarchi

university of munich
H指数:72
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

出版更正:GLP-1R-GIPR-PPARα/γ/δ五重激动作用可纠正小鼠的肥胖与糖尿病

Nature
IF48.5
2026-05-180
OAAI
GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

GLP-1R-GIPR-PPARα/γ/δ五重激动剂纠正小鼠肥胖和糖尿病

Nature
IF48.5
2026-04-010
PRE
A once-daily GLP-1/GIP/glucagon receptor triagonist (NN1706) lowers body weight in rodents, monkeys and humans

一种每日一次的GLP-1/GIP/胰高血糖素受体三激动剂(NN1706)可降低啮齿动物、猴和人体的体重。

2025-06-010
OAAI
Estrogenic activity of E2-conjugated GLP-1 is mediated by intracellular endolysosomal acidification and estrone metabolism

E2共轭GLP-1的雌激素活性由细胞内内体溶酶体酸化和雌酮代谢介导

2025-06-010
OAAI
GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice (Apr, 10.1038/s42255-025-01294-x, 2024)

GIPR激动和拮抗通过不同的机制降低雄性小鼠的体重和食物摄入量(Apr, 10.1038/s42255-025-01294-x, 2024)

2025-05-130
OA
GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice

GIPR激动和拮抗通过不同的机制降低雄性小鼠的体重和食物摄入量。

2025-04-291
OA
Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy
2024-10-010
OAAI
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease( vol 22 , 217 , 2023)

在心脏代谢疾病的临床前小鼠模型中,GIP受体激动作用可改善血脂异常和动脉粥样硬化,而与体重减轻无关 (第22卷,217,2023)

2024-09-120
OAAI
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
2023-11-0921
OA
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

在心脏代谢疾病的临床前小鼠模型中,GIP受体激动可独立于体重减轻而改善血脂异常和动脉粥样硬化

2023-08-176
OAAI
Validation of Mct8/Oatp1c1 dKO mice as a model organism for the Allan-Herndon-Dudley Syndrome
2022-12-014
OAAI